DCSZ-11 is under clinical development by DynamiCure Biotechnology and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DCSZ-11’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DCSZ-11 overview

DCSZ-11 is under development for the treatment of metastatic solid tumors such as metastatic breast cancer, head and neck cancer, colorectal cancer, gastric cancer, non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, ovarian cancer, cervical cancer, glioblastoma multiforme (GBM). The drug candidate is an anti-CD93 monoclonal antibody. It is administered through intravenous route.

DynamiCure Biotechnology overview

DynamiCure Biotechnology (DynamiCure) is a biotechnology company focusing on treatment of cancer, autoimmune, and other diseases. DynamiCure is headquartered in Waltham, Massachusetts, the US.

For a complete picture of DCSZ-11’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.